Tower microneedle minimizes vitreal reflux in intravitreal injection

详细信息    查看全文

• 作者：Chang Yeol Lee (1)
  Yong Sung You (2)
  Sung Ho Lee (3)
  Hyungil Jung (1)
  
• 关键词：Ocuular drug delivery ; Intravitreal injectin ; Microneedle ; Reflux ; Bleb
• 刊名：Biomedical Microdevices
• 出版年：2013
• 出版时间：October 2013
• 年：2013
• 卷：15
• 期：5
• 页码：841-848
• 全文大小：328KB
• 参考文献：1. M.W. Ashraf, S. Tayyaba, A. Nisar, N. Afzulpurkar, D.W. Bodhale, T. Lomas, A. Poyai, A. Tuantranont, Design, fabrication and analysis of silicon hollow microneedles for transdermal drug delivery system for treatment of hemodynamic dysfunctions. Cardiovasc. Eng. 10, 91鈥?08 (2010) CrossRef
  2. T. Avitabile, F. Marano, F. Castiglione, C. Bucolo, M. Cro, L. Ambrosio, C. Ferrauto, A. Reibaldi, Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials 22, 195鈥?00 (2001) CrossRef
  3. R.T. Cortez, G. Ramirez, L. Collet, P. Thakuria, G.P. Giuliari, Intravitreous bevacizumab injection: an experimental study in New Zealand white rabbits. Arch. Ophthalmol. 128, 884鈥?87 (2010) CrossRef
  4. S. Duvvuri, S. Majumdar, A.K. Mitra, Drug delivery to the retina: challenges and opportunities. Expert. Opin. Biol. Ther. 3, 45鈥?6 (2003) CrossRef
  5. A.E. Fung, P.J. Rosenfeld, E. Reichel, The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90, 1344鈥?349 (2006) CrossRef
  6. M. Hornof, E. Toropainen, A. Urtti, Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 60, 207鈥?25 (2005) CrossRef
  7. J. Hsu, Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol. 18, 235鈥?39 (2007) CrossRef
  8. P.M. Hughes, O. Olejnik, J.E. Chang-Lin, C.G. Wilson, Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57, 2010鈥?032 (2005) CrossRef
  9. R.D. Jager, L.P. Aiello, S.C. Patel, E.T. Jr Cunningham, Risks of intravitreous injection: a comprehensive review. Retina 24, 676鈥?98 (2004) CrossRef
  10. K.G. Janoria, S. Gunda, S.H. Boddu, A.K. Mitra, Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. 4, 371鈥?88 (2007) CrossRef
  11. J. Jiang, H.S. Gill, D. Ghate, B.E. McCarey, S.R. Patel, H.F. Edelhauser, M.R. Prausnitz, Coated microneedles for drug delivery to the eye. Invest. Ophthalmol. Vis. Sci. 48, 4038鈥?043 (2007) CrossRef
  12. J. Jiang, J.S. Moore, H.F. Edelhauser, M.R. Prausnitz, Intrascleral drug delivery to the eye using hollow microneedles. Pharm. Res. 26, 395鈥?03 (2009) CrossRef
  13. A. Laude, L.E. Tan, C.G. Wilson, G. Lascaratos, M. Elashry, T. Aslam, N. Patton, B. Dhillon, Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog. Retin. Eye Res. 29, 466鈥?75 (2010) CrossRef
  14. K. Lee, H.C. Lee, D.S. Lee, H. Jung, Drawing lithography: three-dimensional fabrication of an ultrahigh-aspect-ratio microneedle. Adv. Mater. 22, 483鈥?86 (2010) CrossRef
  15. C.Y. Lee, K. Lee, Y.S. You, S.H. Lee, H. Jung, Tower microneedle via reverse drawing lithography for innocuous intravitreal drug delivery. Adv. Healthc. Mater (2012). doi:10.1002/adhm.201200239
  16. K. Lorenz, I. Zwiener, A. Mirshahi, Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch. Clin. Exp. Ophthalmol. 248, 1573鈥?577 (2010) CrossRef
  17. D.W. Lu, C.J. Chang, C.H. Chiang, M.K. Yeh, P.I. Chou, Wound modulation after trabeculectomy by different formulations of antimetabolites in rabbits. J. Ocul. Pharmacol. Ther. 16, 529鈥?38 (2000) CrossRef
  18. D.V. McAllister, P.M. Wang, S.P. Davis, J.H. Park, P.J. Canatella, M.G. Allen, M.R. Prausnitz, Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. U. S. A. 100, 13755鈥?3760 (2003) CrossRef
  19. S.R. Patel, D.E. Berezovsky, B.E. McCarey, V. Zarnitsyn, H.F. Edelhauser, M.R. Prausnitz, Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest. Ophthalmol. Vis. Sci. 53, 4433鈥?441 (2012) CrossRef
  20. G.A. Peyman, E.M. Lad, D.M. Moshfeghi, Intravitreal injection of therapeutic agents. Retina 29, 875鈥?12 (2009) CrossRef
  21. J.S. Pulido, C.M. Pulido, S.J. Bakri, C.A. McCannel, J.D. Cameron, The use of 31-gauge needles and syringes for intraocular injections. Eye 21, 829鈥?30 (2007) CrossRef
  22. E.B. Rodrigues, C.H. Meyer, A. Jr Grumann, H. Shiroma, J.S. Aguni, M.E. Farah, Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am. J. Ophthalmol. 143, 1035鈥?037 (2007) CrossRef
  23. R.P. Singh, H. Bando, O.F. Brasil, D.R. Williams, P.K. Kaiser, Evaluation of wound closure using different incision techniques with 23-gauge and 25-gauge microincision vitrectomy systems. Retina 28, 242鈥?48 (2008) CrossRef
  
• 作者单位：Chang Yeol Lee (1)
  Yong Sung You (2)
  Sung Ho Lee (3)
  Hyungil Jung (1)
  
  1. Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, Republic of Korea
  2. Nune Eye Hospital, Noon Bldg, 907-16 Daechi-dong, Gangnam-gu, Seoul, 135-280, Republic of Korea
  3. Lumieye Genetics, Noon Bldg, 907-16 Daechi-dong, Gangnam-gu, Seoul, 135-280, Republic of Korea
  
• ISSN：1572-8781

文摘

Intravitreal injection is widely used for easy control of drug levels in posterior segment of the eye by injecting the drug directly with hypodermic needles. Patients, however, often experience complications from intravitreal injection due to repeated injections, increased intraocular pressure, and infection. In addition, injected drug reflux after intravitreal injection makes it challenging to maintain predetermined drug dose due to the drug loss through backward effusions. Here, we described that the Tower Microneedle can reduce initial reflux and bleb formation due to its smaller outer diameter compared to a traditional hypodermic needle. Furthermore, we use phenylephrine hydrochloride for pupil expansion and demonstrated that Tower Microneedle induced similar pupil expansions using only half the drug volume, in the same period of time, compared to the 31 Gauge hypodermic needle. Consequently, Tower Microneedle achieves the same therapeutic effect in the vitreous body using fewer drugs than a traditional hypodermic needle due to the decreased backward drug effusion. Tower Microneedle described herein holds great promise for intravitreal injection with less reflux and lower drug dosage.